{
    "id": "0405",
    "question": "A 58-year-old male with a history of obesity and hypertension presents to his primary care physician for a follow-up visit. He reports that he feels well and has no complaints. He currently takes hydrochlorothiazide. His temperature is 98.6\u00b0F (37\u00b0C), blood pressure is 135/80 mmHg, pulse is 86/min, and respirations are 17/min. His BMI is 31 kg/m2. Results of a lipid panel are: Total cholesterol is 280 mg/dl, triglycerides are 110 mg/dl, HDL cholesterol is 40 mg/dl, and LDL cholesterol is 195 mg/dl. Her physician considers starting her on atorvastatin. Which of the following will most likely decrease after initiating this medication?",
    "options": {
        "A": "Mevalonate",
        "B": "Acetoacetyl-CoA",
        "C": "Diacyglycerol",
        "D": "High-density lipoprotein"
    },
    "answer": "A",
    "predict": "Here's the step-by-step thinking and the answer in JSON format: {\"step_by_step_thinking\": \"The patient has a lipid profile that indicates he has hypercholesterolemia, with high total cholesterol, LDL cholesterol, and triglycerides, but low HDL cholesterol. The physician considers starting him on atorvastatin, a statin medication that is commonly used to lower LDL cholesterol and triglycerides, and increase HDL cholesterol. To understand which option will most likely decrease after initiating this medication, we need to consider the metabolic pathway of atorvastatin and its effects on the body.\\n\\nAtorvastatin works by inhibiting HMG-CoA reductase, an enzyme that is involved in the mevalonate pathway. Inhibiting this enzyme reduces the production of mevalonate, which is a precursor to cholesterol. As a result, the body produces less cholesterol, which leads to a decrease in LDL cholesterol and triglycerides. However, atorvastatin also has an effect on the isoprenoid pathway, which is involved in the synthesis of isoprenoids, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These isoprenoids are necessary for the post-translational modification of small GTPases, such as Ras and Rho, which play important roles in various cellular processes, including cell growth, differentiation, and survival.\\n\\nGiven the options, the one that will most likely decrease after initiating atorvastatin is B. Acetoacetyl-CoA. This is because atorvastatin inhibits HMG-CoA reductase, which is also a key enzyme in the mevalonate pathway. As a result, the production of acetoacetyl-CoA, which is a downstream product of mevalonate, will decrease. Acetoacetyl-CoA is involved in various cellular processes, including the synthesis of cholesterol and other isoprenoids. By inhibiting the mevalonate pathway, atorvastatin will lead to a decrease in acetoacetyl-CoA production.\\n\\nThe other options are not directly affected by atorvastatin. Mevalonate (A) will actually increase as a result of atorvastatin, as the inhibition of HMG-CoA reductase leads to an increase in mevalonate production. Diacylglycerol (C) is not directly affected by atorvastatin, as it is not a key intermediate in the mevalonate pathway. High-density lipoprotein (D) may actually increase as a result of atorvastatin, as the medication can increase the levels of HDL cholesterol by reducing the levels of LDL cholesterol and triglycerides.\"} {\"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_4629",
            "title": "Pharmacology_Katzung",
            "content": "A 66-year-old obese Caucasian man presented to an academic Diabetes Center for advice regarding his diabetes treatment. His diabetes was diagnosed 10 years previously on routine testing. He was initially given metformin but when his control deteriorated, the metformin was stopped and insulin treatment initiated. The patient was taking 50 units of insulin glargine and an average of 25 units of insulin aspartate pre-meals. He had never seen a diabetes educator or a dietitian. He was checking his glucose levels 4 times a day. He was smoking half a pack of cigarettes a day. On examination, his weight was 132 kg (BMI 39.5); blood pressure 145/71; and signs of mild peripheral neuropathy were present. Laboratory tests noted an HbA1c value of 8.1%, urine albumin 3007 mg/g creatinine (normal <30), serum creatinine 0.86 mg/dL (0.61\u20131.24), total choles-terol 128 mg/dL, triglycerides 86 mg/dL, HDL cholesterol 38 mg/dL, and LDL cholesterol 73 mg/dL (on atorvastatin 40 mg daily). How would you"
        },
        {
            "id": "Pharmacology_Katzung_7061",
            "title": "Pharmacology_Katzung",
            "content": "A 53-year-old woman with a history of knee osteoarthritis, high cholesterol, type 2 diabetes, and hypertension presents with new onset of hot flashes and a question about a dietary supplement. She is obese (body mass index [BMI] 33), does not exercise, and spends a good portion of her work day in a seated position. She eats a low-sugar diet and regularly eats packaged frozen meals for dinner because she doesn\u2019t have time to cook regularly. Her most recent laboratory values include a low-density lipoprotein (LDL) cholesterol that is above goal at 160 mg/dL (goal < 100 mg/dL) and a hemo-globin A1c that is well controlled at 6%. Her blood pressure is high at 160/100 mm Hg. Her prescription medications include simvastatin, metformin, and benazepril. She also takes over-the-counter ibuprofen for occasional knee pain and a multivitamin supplement once daily. She has heard good things about natural products and asks you if taking a garlic supplement daily could help to bring her blood"
        },
        {
            "id": "First_Aid_Step2_54",
            "title": "First_Aid_Step2",
            "content": "\u25a0LDL > 130 mg/dL or HDL < 40 mg/dL, even if total serum cholesterol is < 200 mg/dL, is diagnostic of dyslipidemia. Based on risk stratification (see Table 2.1-11). Risk factors include diabetes (considered a CAD risk equivalent), smoking, hypertension, HDL < 40 mg/dL, age > 45 (males), age > 55 (females), and early CAD in first-degree relatives (males < 55 and females < 65). The first intervention should be a 12-week trial of diet and exercise in a patient with no known atherosclerotic vascular disease. Commonly used lipid-lowering agents are listed in Table 2.1-12. The BP goal in uncomplicated hypertension is < 140/< 90. For diabetics or patients with renal disease, the goal is < 130/< 80. Defined as a systolic BP > 140 mmHg and/or a diastolic BP > 90 based on three measurements separated in time (see Table 2.1-13). Classified as 1\u00b0 or 2\u00b0."
        },
        {
            "id": "Pharmacology_Katzung_1006",
            "title": "Pharmacology_Katzung",
            "content": "Neal L. Benowitz, MD A 35-year-old man presents with a blood pressure of 150/95 mm Hg. He has been generally healthy, is sedentary, drinks several cocktails per day, and does not smoke cigarettes. He has a family history of hypertension, and his father died of a myocardial infarction at age 55. Physical examination is remarkable only for moderate obesity. Total cholesterol is 220, and high-density lipoprotein (HDL) cholesterol level is 40 mg/dL. Fasting glucose is 105 mg/dL. Chest X-ray is normal. Electrocardiogram shows left ven-tricular enlargement. How would you treat this patient?"
        },
        {
            "id": "InternalMed_Harrison_28057",
            "title": "InternalMed_Harrison",
            "content": "Based on the guidelines provided by the ADA, priorities in the treatment of dyslipidemia are as follows: (1) lower the LDL cholesterol, (2) raise the HDL cholesterol, and (3) decrease the triglycerides. A treatment strategy depends on the pattern of lipoprotein abnormalities. Initial therapy for all forms of dyslipidemia should include dietary changes, as well as the same lifestyle modifications recommended in the nondiabetic population (smoking cessation, blood pressure control, weight loss, increased physical activity). The dietary recommendations for individuals with DM include increased monounsaturated fat and carbohydrates and reduced saturated fats and cholesterol (Chap. 421). According to guidelines of the ADA, the target lipid values in diabetic individuals (age >40 years) without CVD should be as follows: LDL <2.6 mmol/L (100 mg/dL); HDL >1 mmol/L (40 mg/ dL) in men and >13 mmol/L (50 mg/dL) in women; and triglycerides <1.7 mmol/L (150 mg/dL). In patients >40 years, the ADA"
        },
        {
            "id": "Gynecology_Novak_888",
            "title": "Gynecology_Novak",
            "content": "Figure 9.4 is a suggested algorithm for cholesterol control based on LDL levels. Cholesterol fat-lowering diet books abound in most bookstores and allow the patient to choose a diet she will best follow. The role of exercise and cigarette cessation should be stressed to all patients. Patients with a family history of cardiovascular disease (history of premature coronary artery problems and strokes) should be tested and started on conservative programs in their 20s. After 3 to 6 months, if the LDL remains above 160 mg/dL with zero to one risk factor or above 130 mg/dL with two or more risk factors, then medical therapy should be initiated. Any woman with coronary heart disease or equivalents such as diabetes or other forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid artery disease) should initiate lifestyle changes if her LDL is 100 mg/dL or more and drug therapy if her LDL is 130 mg/dL or more. Anyone with an LDL 190"
        },
        {
            "id": "Pharmacology_Katzung_3849",
            "title": "Pharmacology_Katzung",
            "content": "A 42-year-old woman has heterozygous familial hyper-cholesterolemia (HeFH) but is otherwise well and has no symptoms of coronary or peripheral vascular disease. A carotid ultrasound was normal. Her mother had a myo-cardial infarction at age 51 and had no known risk factors other than her presumed HeFH. The patient also has ele-vated lipoprotein (a) at 2.5 times normal and low HDL-C (43 mg/dL). She developed muscle symptoms with each of 3 statins (atorvastatin, rosuvastatin, and simvastatin) so they were discontinued although she did not develop elevated levels of creatine kinase. Her untreated LDL-C is 235 mg/dL and triglycerides 125 mg/dL. Her LDL-C goal for primary prevention of arteriosclerotic vascular disease is in the 70-mg/dL range because of her multiple lipopro-tein risk factors and her mother\u2019s history of premature coronary artery disease. She has no other risk factors and her diet and exercise habits are excellent. How would you manage this patient?"
        },
        {
            "id": "InternalMed_Harrison_28058",
            "title": "InternalMed_Harrison",
            "content": "CVD should be as follows: LDL <2.6 mmol/L (100 mg/dL); HDL >1 mmol/L (40 mg/ dL) in men and >13 mmol/L (50 mg/dL) in women; and triglycerides <1.7 mmol/L (150 mg/dL). In patients >40 years, the ADA recommends addition of a statin, regardless of the LDL level, in patients with CHD and those without CHD who have CHD risk factors. Recently released guidelines by the American College of Cardiology (ACC) and American Heart Association (AHA) differ slightly and recommend that diabetic individuals aged 40\u201375 without CHD and a LDL of 70\u2013189 mg/dl receive \u201cmoderate\u201d intensity statin therapy (Chap. 291e). Improvement in glycemic control will lower triglycerides and have a modest beneficial effect by raising HDL."
        },
        {
            "id": "Pharmacology_Katzung_4630",
            "title": "Pharmacology_Katzung",
            "content": "serum creatinine 0.86 mg/dL (0.61\u20131.24), total choles-terol 128 mg/dL, triglycerides 86 mg/dL, HDL cholesterol 38 mg/dL, and LDL cholesterol 73 mg/dL (on atorvastatin 40 mg daily). How would you treat this patient?"
        },
        {
            "id": "Pharmacology_Katzung_2624",
            "title": "Pharmacology_Katzung",
            "content": "Helge Eilers, MD, & Spencer Yost, MD An elderly man with type 2 diabetes mellitus and ischemic pain in the lower extremity is scheduled for femoral-to-popliteal artery bypass surgery. He has a history of hyper-tension and coronary artery disease with symptoms of stable angina. He can walk only half a block before pain in his legs forces him to stop. He has a 50-pack-year smoking history but stopped 2 years ago. Medications include atenolol, atorvastatin, and hydrochlorothiazide. The nurse in the preoperative holding area obtains the following vital signs: temperature 36.8\u00b0C (98.2\u00b0F), blood pressure 168/100 mm Hg, heart rate 78 bpm, oxygen saturation by pulse oximeter 96% while breathing room air, and pain 5/10 in the right lower leg after walking into the hospital. What anesthetic agents will you choose for his anesthetic plan? Why? Does the choice of anesthetic make a difference?"
        },
        {
            "id": "Surgery_Schwartz_5389",
            "title": "Surgery_Schwartz",
            "content": "statement summarize the secondary prevention recommendations.37 Class I recommendations include smoking cessation and avoid-ance of environmental tobacco exposure, blood pressure con-trol to under 140/90 mmHg (under 130/80 mmHg in those with diabetes or chronic kidney disease), LDL cholesterol levels less than 100 mg/dL, aspirin therapy in all patients without contra-indications, a BMI target of less than 25 kg/m2, diabetes man-agement with target HbA1c <7%, and encouragement of daily moderate-intensity aerobic exercise. \u03b2-Blockers should be used in all patients with LV dysfunction and following MI, ACS, or revascularization, unless a specific contraindication is pres-ent. Renin-angiogensin-aldosterone system blockade in patients with hypertension, LV dysfunction, diabetes, or chronic kidney disease should also be considered.Clinical ManifestationsPatients with CAD may have a spectrum of presentations, including angina pectoris, myocardial infarction, ischemic heart failure,"
        },
        {
            "id": "Pharmacology_Katzung_1490",
            "title": "Pharmacology_Katzung",
            "content": "Ramin Sam, MD, Harlan E. Ives, MD, PhD, & David Pearce, MD A 65-year-old man has a history of diabetes and chronic kidney disease with baseline creatinine of 2.2 mg/dL. Despite five different antihypertensive drugs, his clinic blood pres-sure is 176/92 mm Hg; he has mild dyspnea on exertion and 2\u20133+ edema on exam. He has been taking furosemide 80 mg twice a day for 1 year now. At the clinic visit, hydrochlorothi-azide 25 mg daily is added for better blood pressure control and also to treat symptoms and signs of fluid overload. Two weeks later, the patient presents to the emergency depart-ment with symptoms of weakness, anorexia, and generalized malaise. His blood pressure is now 91/58 mm Hg, and he has lost 15 kg in 2 weeks. His laboratory tests are signifi-cant for a serum creatinine of 10.8 mg/dL. What has led to the acute kidney injury? What is the reason for the weight loss? What precautions could have been taken to avoid this hospitalization?"
        },
        {
            "id": "Pharmacology_Katzung_1130",
            "title": "Pharmacology_Katzung",
            "content": "Irbesartan Generic,Avapro Treatment of Angina Pectoris Bertram G. Katzung, MD, PhD* A 56-year-old woman presents in the office with a history of recent-onset chest discomfort when jogging or swimming vigorously. The pain is dull but poorly localized; it disap-pears after 5\u201310 minutes of rest. She has never smoked but has a history of hyperlipidemia (total cholesterol level of 245 mg/dL and low-density lipoprotein [LDL] of 160 mg/dL recorded 1 year ago) and admits that she has not been fol-lowing the recommended diet. Her father survived a \u201cheart attack\u201d at age 55, and an uncle died of some cardiac disease at age 60. On physical examination, the patient\u2019s blood pressure is 145/90 mm Hg, and her heart rate is 80 bpm. She is in no acute distress, and there are no other significant physical findings; an electrocardiogram is normal except for slight left ventricular hypertrophy. Assuming that a diagno-sis of stable effort angina is correct, what medical treatment should be implemented?"
        },
        {
            "id": "InternalMed_Harrison_28164",
            "title": "InternalMed_Harrison",
            "content": "The presence of a mixed dyslipidemia (plasma TG levels between 200 and 600 mg/dL and total cholesterol levels between 200 and 400 mg/dL, usually with HDL-C levels <40 mg/dL in men and <50 mg/dL in women) and a family history of mixed dyslipidemia and/or premature CHD strongly suggests the diagnosis. Individuals with this phenotype should be treated aggressively due to significantly increased risk of premature CHD. Decreased dietary intake of simple carbohydrates, aerobic exercise, and weight loss can all have beneficial effects on the lipid profile. Patients with diabetes should be aggressively treated to maintain good glucose control. Most patients with FCHL require lipid-lowering drug therapy, starting with statins, to reduce lipoprotein levels and lower the risk of cardiovascular disease."
        },
        {
            "id": "First_Aid_Step2_53",
            "title": "First_Aid_Step2",
            "content": "\u25a0Total serum cholesterol > 200 mg/dL on two different occasions is diagnostic of hypercholesterolemia. T AB LE 2.1 -1 1. ATP III Guidelines for Risk Stratifcation of Hypercholesterolemia CAD or CAD risk equivalentsa < 100 mg/dL (or < 70) > 100 mg/dL > 130 mg/dL 2+ risk factorsb < 130 mg/dL > 130 mg/dL > 160 mg/dL 0\u20131 risk factorb < 160 mg/dL > 160 mg/dL > 190 mg/dL a CAD risk equivalents = symptomatic carotid artery disease, peripheral arterial disease, abdominal aortic aneurysm, diabetes. b Risk factors = cigarette smoking, hypertension, low HDL (< 40 mg/dL), a family history of premature CAD, and age (men > 45 years; women > 55 years). An HDL > 60 mg/dL counts as a \u201cnegative\u201d risk factor and removes one risk factor from the total score. \u25a0LDL > 130 mg/dL or HDL < 40 mg/dL, even if total serum cholesterol is < 200 mg/dL, is diagnostic of dyslipidemia."
        },
        {
            "id": "Pharmacology_Katzung_1764",
            "title": "Pharmacology_Katzung",
            "content": "During a routine check and on two follow-up visits, a 45-year-old man was found to have high blood pressure (160\u2013165/95\u2013100 mm Hg). His physician initially prescribed hydrochlorothiazide, a diuretic commonly used to treat hyper-tension. His blood pressure was reduced by hydrochloro-thiazide but remained at a hypertensive level (145/95 mm Hg), and he was referred to the university hypertension clinic. Because the patient had elevated plasma renin activity and aldosterone concentration, hydrochlorothiazide was replaced with enalapril, an angiotensin-converting enzyme inhibitor. Enalapril lowered his blood pressure to almost normotensive levels. However, after several weeks on enalapril, the patient returned complaining of a persistent cough. In addition, some signs of angioedema were detected. How does enalapril lower blood pressure? Why does it occasionally cause coughing and angioedema? What other drugs could be used to inhibit the renin-angiotensin system and decrease blood pressure,"
        },
        {
            "id": "Gynecology_Novak_5513",
            "title": "Gynecology_Novak",
            "content": "3. A 2-hour post-75-g oral glucose challenge measurement in PCOS women with a BMI greater than 30 kg/m2, or alternatively in lean PCOS women with advanced age (40 years), personal history of gestational diabetes, or family history of type 2 diabetes. 4. Blood pressure measurement at each visit. The ideal blood pressure is 120/80 or lower. Prehypertension should be treated because blood pressure control has the largest benefit in reducing cardiovascular diseases. 5. Regular assessment for depression, anxiety, and quality of life. 130 100 70 160 130 100 LDL target values, mg/dL Non-HDL target values, mg/dL PCOS PCOS with metabolic PCOS with metabolic syndrome syndrome and Type 2 diabetes mellitus, overt vascular and/or renal disease"
        },
        {
            "id": "InternalMed_Harrison_28282",
            "title": "InternalMed_Harrison",
            "content": "Hypertension: blood pressure \u2265130 mmHg systolic or HDL cholesterol level <40 mg/dL and <50 mg/dL for men and women, respectively, or \u2022 Fasting plasma glucose level \u2265100 mg/dL (alternative indication: drug treatment of aNational Cholesterol Education Program and Adult Treatment Panel III. bIn this analysis, the following thresholds for waist circumference were used: white men, \u226594 cm; African-American men, \u226594 cm; Mexican-American men, \u226590 cm; white women, \u226580 cm; African-American women, \u226580 cm; Mexican-American women, \u226580 cm. For participants whose designation was \u201cother race\u2014including multiracial,\u201d thresholds that were once based on Europid cutoffs (\u226594 cm for men and \u226580 cm for women) and on South Asian cutoffs (\u226590 cm for men and \u226580 cm for women) were used. For participants who were considered \u201cother Hispanic,\u201d the International Diabetes Federation thresholds for ethnic South and Central Americans were used. cHigh-density lipoprotein."
        },
        {
            "id": "First_Aid_Step2_179",
            "title": "First_Aid_Step2",
            "content": "Strict BP control to < 130/80; ACEIs/ARBs are usually first-line agents. Antiplatelet agents (ASA) for patients at risk of cardiovascular disease or for those > 40 years of age. Regular screening for cardiovascular disease, nephropathy, retinopathy, neuropathy, and smoking cessation. See Table 2.3-2 for an outline of the complications of DM. Note that the presence of diabetes is equivalent to the highest risk for cardiovascular disease regardless of all other risk factors. Also known as insulin resistance syndrome or syndrome X. Associated with an \u2191 risk of CAD and mortality from a cardiovascular event. Presents with abdominal obesity, high BP, impaired glycemic control, and dyslipidemia. Three out of five of the following criteria must be met: Abdominal obesity (\u2191 waist girth): > 40 inches in men and > 35 inches in women. Triglycerides \u2265 150 mg/dL. HDL < 40 mg/dL in men and < 50 mg/dL in women. BP \u2265 130/85 mmHg or administration of antihypertensive drugs."
        },
        {
            "id": "Pharmacology_Katzung_1127",
            "title": "Pharmacology_Katzung",
            "content": "The patient has Joint National Committee stage 1 hyperten-sion (see Table 11\u20131). The first question in management is how urgent is it to treat the hypertension. Cardiovascular risk factors in this man include family history of early coro-nary disease and elevated cholesterol. Evidence of end-organ impact includes left ventricular enlargement on electro-cardiogram. The strong family history suggests that this patient has essential hypertension. However, the patient should undergo the usual screening tests including renal func-tion, thyroid function, and serum electrolyte measurements. An echocardiogram should also be considered to determine whether the patient has left ventricular hypertrophy secondary to valvular or other structural heart disease as opposed to hypertension. Initial management in this patient can be behavioral, including dietary changes and aerobic exercise. However, most patients like this will require medication. Thiazide diuretics in low doses are inexpensive, have"
        },
        {
            "id": "Pharmacology_Katzung_4785",
            "title": "Pharmacology_Katzung",
            "content": "This patient had significant insulin resistance, taking about 125 units of insulin daily (approximately 1 unit per kilogram). He had had limited instruction on how to manage his dia-betes. He had peripheral neuropathy, proteinuria, low HDL cholesterol levels, and hypertension. The patient underwent multifactorial intervention targeting his weight, glucose levels, and blood pressure. He was advised to stop smoking. He attended structured diabetes classes and received indi-vidualized instruction from a diabetes educator and a dieti-tian. Metformin therapy was reinitiated and his insulin doses were reduced. The patient was then given the GLP1 receptor agonist, exenatide. The patient lost about 8 kg in weight over the next 3 years and was able to stop his insulin. He had excellent control with an HbA1c of 6.5 % on a combination of metformin, exenatide, and glimepiride. His antihyperten-sive therapy was optimized and his urine albumin excretion declined to 1569 mg/g creatinine. This case"
        },
        {
            "id": "InternalMed_Harrison_19134",
            "title": "InternalMed_Harrison",
            "content": "1588 DYSLIPIDEMIA The treatment of dyslipidemia is central in aiming for long-term relief from angina, reduced need for revascularization, and reduction in myocardial infarction and death. The control of lipids can be achieved by the combination of a diet low in saturated and trans-unsaturated fatty acids, exercise, and weight loss. Nearly always, HMG-CoA reductase inhibitors (statins) are required and can lower LDL cholesterol (25\u201350%), raise HDL cholesterol (5\u20139%), and lower triglycerides (5\u201330%). A powerful treatment effect of statins on atherosclerosis, IHD, and outcomes is seen regardless of the pretreatment LDL cholesterol level. Fibrates or niacin can be used to raise HDL cholesterol and lower triglycerides (Chaps. 291e and 421). Controlled trials with lipid-regulating regimens have shown equal proportional benefit for men, women, the elderly, diabetic patients, and smokers. Compliance with the health-promoting behaviors listed above is generally very poor, and a conscientious"
        },
        {
            "id": "Pharmacology_Katzung_1333",
            "title": "Pharmacology_Katzung",
            "content": "The patient has a low ejection fraction with systolic heart failure, probably secondary to hypertension. His heart fail-ure must be treated first, followed by careful control of the hypertension. He was initially treated with a diuretic (furo-semide, 40 mg twice daily). On this therapy, he was less short of breath on exertion and could also lie flat without dyspnea. An angiotensin-converting enzyme (ACE) inhib-itor was added (enalapril, 20 mg twice daily), and over the next few weeks, he continued to feel better. Because of continued shortness of breath on exercise, digoxin at 0.25 mg/d was added with a further modest improvement in exercise tolerance. The blood pressure stabilized at 150/90 mm Hg, and the patient will be educated regarding the relation between his hypertension and heart failure and the need for better blood pressure control. Cautious addition of a \u03b2 blocker (metoprolol) will be considered. Blood lipids, which are currently in the normal range, will be monitored."
        },
        {
            "id": "InternalMed_Harrison_19010",
            "title": "InternalMed_Harrison",
            "content": "As the prevalence of metabolic syndrome and diabetes increases, many patients present with low concentrations of HDL (HDL cholesterol <1.0 mmol/L [<40 mg/dL]). A baseline measurement of HDL cholesterol indubitably correlates with future cardiovascular risk. Yet, the utility of therapies that raise HDL cholesterol levels in blood as effective interventions to reduce cardiovascular vascular events has come into question. Blood HDL levels vary inversely with those of triglycerides, and the independent role of HDL versus triglycerides as a cardiovascular risk factor remains unsettled. The 2013 guideline does not advocate any specific therapy for raising HDL. Indeed, multiple recent trials failed to show that raising HDL cholesterol levels improves cardiovascular outcomes, and recent genetic studies cast doubt on low HDL as a causal risk factor for atherosclerotic events. Weight loss and physical activity can raise HDL, and these lifestyle measures merit universal adoption (Table 291e-3)."
        },
        {
            "id": "InternalMed_Harrison_32551",
            "title": "InternalMed_Harrison",
            "content": "Cholesterol (LCL, Total, HDL): Ranges depend on individual patient factors; see 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol Cholinesterase S 5\u201312 kU/L 5\u201312 U/mL Chromogranin A S 0\u201395 \u03bcg/L 0\u201395 ng/mL Complement S 0.83\u20131.77 g/L 83\u2013177 mg/dL C4 0.16\u20130.47 g/L 16\u201347 mg/dL Complement total Cortisol Fasting, 8 A.M.\u201312 noon S 138\u2013690 nmol/L 5\u201325 \u03bcg/dL 12 noon\u20138 P.M. 138\u2013414 nmol/L 5\u201315 \u03bcg/dL 8 P.M.\u20138 A.M. 0\u2013276 nmol/L 0\u201310 \u03bcg/dL C-reactive protein S <10 mg/L <10 mg/L C-reactive protein, high sensitivity S Cardiac risk Cardiac risk Low: <1.0 mg/L Low: <1.0 mg/L Average: 1.0\u20133.0 mg/L Average: 1.0\u20133.0 mg/L High: >3.0 mg/L High: >3.0 mg/L Laboratory Values of Clinical Importance Laboratory Values of Clinical Importance Laboratory Values of Clinical Importance Laboratory Values of Clinical Importance"
        },
        {
            "id": "InternalMed_Harrison_17264",
            "title": "InternalMed_Harrison",
            "content": "Despite the value of invasive tests in certain circumstances, they entail some small risk to the patient, involve discomfort and substantial cost, and place a strain on medical facilities. Therefore, they should be carried out only if the results can be expected to modify the patient\u2019s management. The prevention of heart disease, especially of CAD, is one of the most important tasks of primary care health givers as well as cardiologists. Prevention begins with risk assessment, followed by attention to lifestyle, such as achieving optimal weight, physical activity, and smoking cessation, and then aggressive treatment of all abnormal risk factors, such as hypertension, hyperlipidemia, and diabetes mellitus (Chap. 417). After a complete diagnosis has been established in patients with known heart disease, a number of management options are usually available. Several examples may be used to demonstrate some of the 1441 principles of cardiovascular therapeutics: 1."
        },
        {
            "id": "Biochemistry_Lippincott_1323",
            "title": "Biochemistry_Lippinco",
            "content": "For Questions 27.7 and 27.8, use the following case. A sedentary 50-year-old man weighing 176 lb (80 kg) requests a physical. He denies any health problems. Routine blood analysis is unremarkable except for plasma total cholesterol of 295 mg/dl. (Reference value is <200 mg.) The man refuses drug therapy for his hypercholesterolemia. Analysis of a 1-day dietary recall showed the following: 7.4. Decreasing which one of the following dietary components would have the greatest effect in lowering the patient\u2019s plasma cholesterol? A. Carbohydrates B. Cholesterol C. Fiber D. Monounsaturated fat E. Polyunsaturated fat F. Saturated fat"
        },
        {
            "id": "Pharmacology_Katzung_7019",
            "title": "Pharmacology_Katzung",
            "content": "Her social history is significant for alcohol use (three to four glasses of wine/night). Her vital signs include the following: temperature 99.8\u00b0F, blood pressure 132/64 mm Hg, pulse 78 bpm, and respiratory rate 15/min. On physical examination, she had left upper abdominal tenderness with evidence of hepatomegaly and mild scleral icterus. Laboratory data revealed the following: alanine aminotransferase, 527 IU/L (normal 10\u201335 IU/L); aspartate aminotransferase, 425 IU/L (normal < 35 IU/L); and bilirubin, 2.9 mg/dL (normal 0.1\u20130.3 mg/dL). What medications do OTC cold and flu preparations typically contain? Which of the OTC medications might have contrib-uted to the patient\u2019s current symptoms? KH, a 55-year-old woman, presents to the emergency department with nausea, vomiting, and complaints of new-onset flu symptoms over the past several days. Her past medical history is significant for allergic rhinitis and chronic lower back pain secondary to a work-related fall 2 years ago. Her"
        },
        {
            "id": "Pharmacology_Katzung_3864",
            "title": "Pharmacology_Katzung",
            "content": "Lipoprotein disorders are detected by measuring lipids in serum after a 10-hour fast. Risk of heart disease increases with concentrations of the atherogenic lipoproteins, is inversely related to levels of HDL-C, and is modified by other risk factors. Evidence from clinical trials suggests that an LDL cholesterol (LDL-C) level of 50-60 mg/dL is optimal for patients with coronary disease. Ideally, triglycerides should be below 120 mg/dL. Although LDL-C is still the primary target of treatment, reducing the levels of VLDL and IDL also is important. Calculation of non-HDL cholesterol provides a means of assessing levels of all the lipoproteins in the VLDL to LDL cascade. Differentiation of the disorders requires identification of the lipoproteins involved (Table 35\u20131). Diagnosis of a primary disorder usually requires further clinical and TABLE 35\u20131 The primary hyperlipoproteinemias and their treatment."
        },
        {
            "id": "Obstentrics_Williams_327",
            "title": "Obstentrics_Williams",
            "content": "Maternal hyperlipidemia is one of the most consistent and striking changes of lipid metabolism during late pregnancy. Triacylglycerol and cholesterol levels in very-low-density lipoproteins (VLDLs), low-density lipoproteins (LDLs), and highdensity lipoproteins (HDLs) are increased during the third trimester compared with those in nonpregnant women. During the third trimester, the average level of total serum cholesterol is 267 \u00b1 30 mg/dL, ofLDL-C is 136 \u00b1 33 mg/dL, ofHDL-C is 81 \u00b1 17 mg/dL, and of triglycerides is 245 \u00b1 73 mg/dL (Lippi, 2007). After delivery, the concentrations of these lipids, lipoproteins, and apolipoproteins decline. Breastfeeding drops maternal triglyceride levels but increases those of HDL-C. The efects of breastfeeding on total cholesterol and LDL-C levels are unclear (Gunderson, 2014)."
        },
        {
            "id": "Pharmacology_Katzung_4939",
            "title": "Pharmacology_Katzung",
            "content": "A 45-year-old man is brought to the local hospital emer-gency department by ambulance. His wife reports that he had been in his normal state of health until 3 days ago when he developed a fever and a productive cough. Dur-ing the last 24 hours he has complained of a headache and is increasingly confused. His wife reports that his medical history is significant only for hypertension, for which he takes hydrochlorothiazide and lisinopril, and that he is allergic to amoxicillin. She says that he developed a rash many years ago when prescribed amoxicillin for bron-chitis. In the emergency department, the man is febrile (38.7\u00b0C [101.7\u00b0F]), hypotensive (90/54 mmHg), tachypneic (36/min), and tachycardic (110/min). He has no signs of meningismus but is oriented only to person. A stat chest x-ray shows a left lower lung consolidation consistent with pneumonia. A CT scan is not concerning for lesions or elevated intracranial pressure. The plan is to start empiric antibiotics and perform a"
        },
        {
            "id": "InternalMed_Harrison_3641",
            "title": "InternalMed_Harrison",
            "content": "A 76-year-old woman presented with a several-month history of diarrhea, with marked worsening over the 2\u20133 weeks before admission (up to 12 stools a day). Review of systems was negative for fever, orthostatic dizziness, nausea and vomiting, or headache. Past medical history included hypertension, kidney stones, and hypercholesterolemia; medications included atenolol, spironolactone, and lovastatin. She also reliably consumed >2 L of liquid per day in management of the nephrolithiasis. The patient received 1 L of saline over the first 5 h of her hospital admission. On examination at hour 6, the heart rate was 72 sitting and 90 standing, and blood pressure was 105/50 mmHg lying and standing. Her jugular venous pressure (JVP) was indistinct with no peripheral edema. On abdominal examination, the patient had a slight increase in bowel sounds but a nontender abdomen and no organomegaly."
        }
    ],
    "scores": [
        0.038748922102281716,
        0.03745734553050096,
        0.034326309245779535,
        0.033757990526299464,
        0.030192287403464774,
        0.029461083724168054,
        0.028459285485211462,
        0.02793192990084182,
        0.026238641438042165,
        0.02607043207679324,
        0.025624085384893587,
        0.025348749231569486,
        0.025265122771516633,
        0.024714847885579594,
        0.023852022683115613,
        0.023404094583364808,
        0.02312289008379803,
        0.02302484082145099,
        0.022675879808101367,
        0.022315565658421462,
        0.02160689286159304,
        0.021320357776072402,
        0.02130787538168533,
        0.02111928507949047,
        0.01959913506320692,
        0.01886960391633289,
        0.01878969654199012,
        0.01852010631912887,
        0.018485705881529,
        0.017879948914431672,
        0.01770050125313283,
        0.017542515703998774
    ]
}